Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 86 results for menopause

  1. Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence (TA1086)

    Evidence-based recommendations on ribociclib (Kisqali) with an aromatase inhibitor for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

    Technology appraisal guidance
    Published
    6 August 2025

    Sections for TA1086

  2. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for uterine prolapse

    The choice of surgery will also be affected by whether you have had your menopause or not, any previous surgery you may have had, and...

  3. Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)

    Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.

    Technology appraisal guidance
    Published
    19 October 2022
    View recommendations

    Sections for TA832

  4. Effects of HRT on breast cancer risk:- What is the difference in the risk of breast cancer in menopausal women on HRT with progesterone, progestogen or selective oestrogen receptor modulators?

    symptoms. Source guidance details Comes from guidance Menopause: identification and management Number NG23 Date issued

    Research recommendation
    Published
    11 December 2015

  5. Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA836)

    Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.

    Technology appraisal guidance
    Published
    26 October 2022
    View recommendations

    Sections for TA836

  6. Women with breast cancer:- What is the safety and effectiveness of alternatives to systemic HRT as treatments for menopausal symptoms in women who have had treatment for breast cancer?

    treatment. Source guidance details Comes from guidance Menopause: identification and management Number NG23 Date issued

    Research recommendation
    Published
    11 December 2015

  7. Benefits of MRI surveillance in women over 50 years:- Research is recommended to establish the risk and benefits of MRI surveillance compared with mammography in women over 50 years with a personal history of breast cancer. Studies should include sub-analysis for breast density. [new 2013]

    Although breast density decreases with age, and particularly after the menopause, there is no sudden change at any particular age. For...

    Research recommendation
    Published
    9 June 2015

  8. Effects of HRT on venous thromboembolism risk:- How does the preparation of HRT affect the risk of venous thromboembolism (VTE)?

    indicated. Source guidance details Comes from guidance Menopause: identification and management Number NG23 Date issued

    Research recommendation
    Published
    11 December 2015

  9. Laparoscopic removal of uterine fibroids with power morcellation (IPG703)

    Evidence-based recommendations on laparoscopic removal of uterine fibroids with power morcellation in adults. This involves cutting the fibroids into small pieces to remove them.

    Interventional procedures guidance
    Published
    25 August 2021
    View recommendations

    Sections for IPG703

  10. Liposuction for chronic lipoedema (IPG721)

    Evidence-based recommendations on liposuction for chronic lipoedema in adults. This involves using suction to remove abnormal fat.

    Interventional procedures guidance
    Published
    29 March 2022
    View recommendations

    Sections for IPG721

  11. Early and locally advanced breast cancer: diagnosis and management (NG101)

    This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.

    NICE guideline
    Last updated
    14 April 2025
    View recommendations

    Sections for NG101

  12. Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)

    Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.

    Technology appraisal guidance
    Published
    21 June 2023
    View recommendations

    Sections for TA904

  13. Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)

    Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age.

    Technology appraisal guidance
    Published
    16 April 2025

    Sections for TA1057

  14. Heavy menstrual bleeding: assessment and management (NG88)

    This guideline covers assessing and managing heavy menstrual bleeding (menorrhagia). It aims to help healthcare professionals investigate the cause of heavy periods that are affecting a woman’s quality of life and to offer the right treatments, taking into account the woman’s priorities and preferences.

    NICE guideline
    Last updated
    24 May 2021
    View recommendations

    Sections for NG88

  15. Indicator advisory committee members

    Read biographies for all members of NICE's indicator advisory committee.